Editas Medicine, Inc. (NASDAQ:EDIT)’s share price rose 0% during trading on Friday . The company traded as high as $24.47 and last traded at $24.38. Approximately 753,699 shares were traded during trading, a decline of 18% from the average daily volume of 918,723 shares. The stock had previously closed at $24.38.

EDIT has been the subject of a number of research analyst reports. Cowen and Company reissued a “buy” rating on shares of Editas Medicine in a report on Tuesday. Zacks Investment Research upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Friday. Morgan Stanley restated an “equal weight” rating and issued a $28.00 price target (up from $27.00) on shares of Editas Medicine in a research report on Friday, October 6th. SunTrust Banks, Inc. started coverage on Editas Medicine in a research report on Thursday, July 13th. They issued a “hold” rating and a $17.00 price target for the company. Finally, ValuEngine upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $26.73.

The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.74 and a current ratio of 6.74.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). The company had revenue of $6.28 million during the quarter, compared to analysts’ expectations of $2.66 million. Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.43%. Editas Medicine’s revenue for the quarter was up 553.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.59) earnings per share. sell-side analysts anticipate that Editas Medicine, Inc. will post -2.88 earnings per share for the current fiscal year.

In related news, CEO Katrine Bosley sold 10,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $20.42, for a total value of $204,200.00. Following the completion of the transaction, the chief executive officer now directly owns 1,414,629 shares in the company, valued at $28,886,724.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 43,332 shares of company stock valued at $946,504 over the last quarter. 19.40% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the stock. IHT Wealth Management LLC purchased a new position in Editas Medicine in the second quarter worth approximately $107,000. Great West Life Assurance Co. Can grew its position in Editas Medicine by 519.9% in the third quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after acquiring an additional 4,159 shares during the period. Bank of America Corp DE grew its position in Editas Medicine by 72.2% in the first quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after acquiring an additional 2,489 shares during the period. DekaBank Deutsche Girozentrale purchased a new position in Editas Medicine in the second quarter worth approximately $127,000. Finally, Legal & General Group Plc grew its position in Editas Medicine by 308.4% in the second quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after acquiring an additional 6,535 shares during the period. Institutional investors own 70.51% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/editas-medicine-inc-edit-stock-price-up-0/1694320.html.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.